Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carelizumab Combined With Irinotecan and Apatinib in Advanced Gastric Cancer
NCT04934618Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2020
- Primary completion
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04934618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934618.